Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled

Title:Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled

Volume: 5

Author(s): Irina Veytsman, Jeanny B. Aragon-Ching and Sandra M. Swain

Affiliation:

Keywords: Angiogenesis, angiogenesis inhibitors, bevacizumab, CNS neoplasm

Abstract: The incidence of central nervous system (CNS) metastases secondary to solid tumors is increasing. As more effective systemic therapy is being used in patients with solid tumors, patients with cancer live longer and are ultimately at higher risk for CNS metastases. However, CNS metastases remain challenging to treat because of limited available therapeutic options. This article reviews mechanisms of CNS metastases, the use of bevacizumab and other angiogenesis inhibitors in the treatment of recurrent and front-line CNS metastases, as well as emerging issues of resistance to antiangiogenic therapy.

Cite this article as:

Veytsman Irina, B. Aragon-Ching Jeanny and M. Swain Sandra, Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled, Current Molecular Pharmacology 2012; 5 (3) . https://dx.doi.org/10.2174/1874467211205030007